奎尔塞丁通过增强肠道屏障功能来促进肠道微生物驱动的异酸的产生
Liang Lei1,2, Jing Wang3, Juanjuan Wang3
1Central Laboratory, Wuhan Fourth Hospital, Wuhan, China.
Current research in food science
|September 5, 2025
概括
通过促进肠道微生物异酸 (IVA) 的产生来缓解性结肠炎 (UC),从而增强肠道屏障功能. 这项研究揭示了肠道微生物群-IVA-肠道屏障轴是素的关键.
科学领域:
- 胃肠病学
- 微生物学
- 药理学
背景情况:
- 性结肠炎是一种慢性炎症性肠病,治疗选择有限.
- 肠道微生物失调和肠道屏障功能受损是UC的特征.
- 昆素是一种植物性黄素,具有抗炎和微生物群调节的特性,但其在UC中的机制尚不清楚.
研究的目的:
- 调查肠道微生物群-异酸 (IVA) -肠道屏障轴在素抗结肠炎作用中的作用.
- 阐明素如何调节肠道微生物群以产生IVA并改善UC的肠道屏障功能.
主要方法:
- 16S rDNA测序以分析肠道微生物组成.
- 代谢学测量异酸 (IVA) 的含量.
- 在大肠炎模型中,使用或不使用IVA补充剂,给药素和抗生素 (ABX).
主要成果:
- 通过调节肠道微生物群,奎思治疗增加了IVA的产生,特别是增加了*Clostridium_XIVa*和*Clostridium_XI*.
- 抗生素诱导的肠道微生物枯竭降低了IVA水平,并消除了奎思对结肠炎的有益作用.
- 仅IVA补充剂可以改善结肠炎和增强肠道屏障功能,模仿奎尔素的作用.
结论:
- 在性结肠炎的治疗效果中,肠道微生物群衍生的IVA至关重要.
- 肠道微生物群-IVA-肠道屏障轴代表了UC的新疗法目标.
- 奎尔塞丁和IVA具有治疗大肠炎和其他肠道炎症的潜力.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
201
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
201
Drugs for Treatment of Diarrhea-Predominant IBS
289
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
289
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
316
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
316
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264


